| Morning all, Craig McGlashan here with the Europe Wire from the London newsroom. This morning we speak to Archimed’s Denis Ribon about his private equity firm’s acquisition of FIM Medical and its M&A plans for the provider of vision, hearing and respiratory care products. Next, MiddleGround Capital has wrapped up its take-private ofa machine and artificial vision technology provider. We then look at DC Advisory’s ‘European Private Equity Mid-Market Monitor: Q3 2024 and Outlook’ report, released this morning, which is cautiously optimistic on dealmaking for next year. Finally, the outcome of the US election is beginning to look clear as I write. I’d love to get readers’ thoughts on what impact the result will have on dealmaking in Europe and globally. Send them to me at [email protected] Cross-border push Archimed plans to turn Lyon, France-based FIM Medical into an international company by making add-on acquisitions in Europe, chairman and managing partner Denis Ribon told PE Hub’s Sophie Rose. Find out more about the plans, Archimed’s activity in the neuro, sensory and occupational health sectors, and Ribon’s outlook for healthcare investing in the premium version of the Wire. Vision play MiddleGround Capital has completed its voluntary public takeover offer of Stemmer Imaging, a provider of machine and artificial vision technology. Read more in the premium version of the Wire. ‘Mindset shift’ There are “reasons to be positive” about mid-market dealmaking in Europe next year, according to investment bank DC Advisory’s ‘European Private Equity Mid-Market Monitor: Q3 2024 and Outlook’ report, released this morning. Find out why in the premium version of the Wire. OK, that’s all from me today. Rafael Canton will write to you with the US Wire later today and I’ll be back on Europe duty tomorrow. Cheers, Craig Read the full Wire commentary on PE Hub ... | 